8-K: Elicio ELI-002 Phase 1 Data Published in Nature Medicine

Elicio Therapeutics announced the publication of positive follow-up data from its Phase 1 AMPLIFY-201 study of ELI-002 in Nature Medicine, showing significant survival benefits.

Summary

• Elicio Therapeutics announced the publication of follow-up data from its Phase 1 AMPLIFY-201 study evaluating ELI-002 in Nature Medicine.
• The study focused on minimal residual disease (MRD) positive, adjuvant-stage patients with solid tumors (20 pancreatic ductal adenocarcinoma, 5 colorectal).
• At an extended median follow-up of 19.7 months, median overall survival (OS) for the 25-patient cohort increased from 16.33 to 28.94 months.
• Clinical efficacy correlated with the magnitude of T cell responses specific to mutant-KRAS (mKRAS) induced by ELI-002.
• Patients with T cell responses above the anti-tumor efficacy threshold experienced an 88% reduction in the risk of progression or death and a 77% reduction in the risk of death.
• ELI-002 induced both CD4+ and CD8+ mKRAS-specific T cell responses in 84% of patients (100% at recommended Phase 2 dose).
• Antigen-spreading, where the immune system recognized additional patient-specific neoantigens, was observed in 67% of patients.
• ELI-002 was well tolerated with no safety concerns, dose-limiting toxicities, or Grade 3 treatment-related adverse events.

Sentiment

Score: 9

Explanation: The filing presents highly positive clinical data from the Phase 1 study, demonstrating significant improvements in overall survival and relapse-free survival, strong immune responses, and a favorable safety profile. The publication in Nature Medicine and the positive recommendation from the Independent Data Monitoring Committee for the Phase 2 study further validate the company's platform and lead candidate.

Positives

• Median overall survival (OS) for the 25-patient cohort significantly increased from 16.33 months to 28.94 months at extended follow-up.
• Patients with T cell responses above the efficacy threshold showed an 88% reduction in the risk of progression or death.
• Patients with T cell responses above the efficacy threshold showed a 77% reduction in the risk of death.
• ELI-002 successfully induced both CD4+ and CD8+ mKRAS-specific T cell responses in 84% of patients, and 100% at the recommended Phase 2 dose.
• Antigen-spreading, indicating a broader anti-tumor immune response, was observed in 67% of patients.
• Tumor biomarker responses were observed in 84% of patients, with complete biomarker clearance in 24% (6/25 patients).
• The drug was well tolerated with no safety concerns, dose-limiting toxicities, or Grade 3 treatment-related adverse events.
• The Independent Data Monitoring Committee recommended the ongoing Phase 2 AMPLIFY-7P study continue without modification to final DFS analysis.

Risks

• Actual results may differ materially from forward-looking statements, as no forward-looking statement can be guaranteed.
• Risks are associated with the development and commercialization plans for product candidates, including ELI-002.
• The timing of initiation of planned clinical trials is subject to uncertainties.
• The timing of the availability of data from clinical trials, including the event-driven final DFS analysis from the Phase 2 AMPLIFY-7P trial anticipated in Q4 2025, may vary.
• Uncertainties exist regarding the timing of any planned investigational new drug application (IND) or new drug application (NDA).
• Estimates regarding future revenue, expenses, capital requirements, and the need for additional financing may not be accurate.
• New factors may emerge that are unpredictable, and their impact on the business cannot be fully assessed.

Future Outlook

Elicio anticipates the final event-driven disease-free survival (DFS) analysis for the randomized Phase 2 AMPLIFY-7P study evaluating ELI-002 7P monotherapy in pancreatic ductal adenocarcinoma (PDAC) in Q4 2025. The company plans to expand ELI-002 to other indications, including mKRAS positive lung cancer and other mKRAS positive cancers. Elicio's pipeline also includes additional off-the-shelf therapeutic cancer vaccine candidates, ELI-007 for BRAF-driven cancers and ELI-008 for p53 hotspot mutations.

Management Comments

• Robert Connelly, CEO: "This publication, combined with the early promising clinical data we've generated to date, further strengthens our belief that our Amphiphile (AMP) platform represents a potentially transformative approach in the treatment of mKRAS-driven tumors."
• Chris Haqq, CMO: "The updated Phase 1 AMPLIFY-201 data further demonstrate that the AMP platform has the potential to provide durable benefit to PDAC patients in the adjuvant setting. These promising results together with the recent positive recommendation from the Independent Data Monitoring Committee that the randomized ongoing Phase 2 AMPLIFY-7P study should continue without modification to final DFS analysis, represent critical advancements for our promising lead program."

Industry Context

Elicio Therapeutics operates in the highly competitive clinical-stage biotechnology sector, specifically focusing on novel immunotherapies for high-prevalence cancers driven by mKRAS mutations. The company's Amphiphile (AMP) platform aims to enhance T cell education and activation by targeting lymph nodes, differentiating it from conventional vaccination strategies. The focus on 'off-the-shelf' vaccines like ELI-002 positions Elicio to potentially offer advantages in cost, rapid manufacturing, and patient accessibility compared to personalized vaccine approaches, which are gaining traction in the cancer vaccine space.

Comparison to Industry Standards

• The filing highlights the potential benefits of off-the-shelf vaccine approaches, such as low cost, rapid commercial scale manufacturing, and rapid drug availability, contrasting them with personalized vaccine approaches.
• While the filing mentions 'recent clinical successes in the personalized cancer vaccine space,' it does not name specific comparable companies, projects, or results for direct comparison.
• The observed median overall survival of 28.94 months and relapse-free survival of 16.33 months in a challenging patient population (MRD positive, adjuvant-stage PDAC and colorectal cancer) are notable, especially with the strong correlation to T-cell responses and antigen-spreading, suggesting a potentially superior immune response compared to non-lymph node targeted approaches, as indicated by Elicio's preclinical models.

Stakeholder Impact

• Shareholders: Positive clinical data and publication in a prestigious journal could lead to increased investor confidence and potential share price appreciation.
• Patients: The promising results of ELI-002 offer potential new treatment options for patients with mKRAS-driven cancers, particularly those with minimal residual disease.
• Employees: Positive clinical advancements can boost morale and validate the company's research and development efforts.
• Medical Community: The publication in Nature Medicine enhances the scientific credibility of Elicio's AMP platform and ELI-002, potentially encouraging further research and collaboration.

Next Steps

• Final event-driven disease-free survival (DFS) analysis for the randomized Phase 2 AMPLIFY-7P study evaluating ELI-002 7P monotherapy in pancreatic ductal adenocarcinoma (PDAC) is anticipated in Q4 2025.
• Plans to expand ELI-002 to other indications, including mKRAS positive lung cancer and other mKRAS positive cancers.
• Continued development of pipeline candidates ELI-007 (BRAF-driven cancers) and ELI-008 (p53 hotspot mutations).

Key Dates

Recommendation

The filing details highly compelling Phase 1 clinical data for ELI-002, demonstrating a significant increase in median overall survival (from 16.33 to 28.94 months) and substantial reductions in the risk of death (77%) and relapse (88%) in a challenging patient population. The strong correlation between T-cell responses and clinical efficacy, coupled with observed antigen-spreading, validates the underlying Amphiphile platform. The publication in a top-tier journal like Nature Medicine and the positive recommendation from the Independent Data Monitoring Committee for the ongoing Phase 2 study further de-risk the program. This represents a major positive catalyst, indicating strong therapeutic potential and a clear path forward for a lead asset targeting a high-prevalence cancer mutation.

Keywords

Elicio Therapeutics, ELI-002, AMPLIFY-201, Phase 1, Nature Medicine, mKRAS, Pancreatic Cancer, Colorectal Cancer, Immunotherapy, Cancer Vaccine, Amphiphile Platform, Oncology, Biotechnology, Clinical Trial, Overall Survival, Relapse-Free Survival, T Cell Response, Minimal Residual Disease